

Evaluation of wrist splinting for the treatment of carpal tunnel syndrome

Submission date 24/04/2018	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 02/05/2018	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 25/03/2026	Condition category Nervous System Diseases	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Carpal tunnel syndrome (CTS) is pressure on a nerve in the wrist that causes tingling, numbness and pain in the hand and fingers. It is commonly treated with wrist splinting, mainly during night-time, but the evidence for the effectiveness and durability of this treatment is weak. The most common type of splint used in current clinical practice is a rigid splint that immobilizes the wrist. However, it has not been established whether a rigid splint is better than a soft splint that does not immobilize the wrist. The aim of this study is to assess the effectiveness of a rigid wrist splint compared with that of a soft wrist splint in patients with CTS.

Who can participate?

Patients aged 25 to 65 with CTS

What does the study involve?

Participants are randomly allocated to treatment with either a rigid or soft wrist splint to be used at night and if possible during daytime, at first for 6 weeks. The splints are fitted with a temperature monitoring device to measure the total time during which the splint has actually been worn. The participants complete a questionnaire that measures CTS symptoms, health status, quality of life and pain at the start of treatment and after 6, 12, 24 and 52 weeks. The participants undergo physical examinations and nerve conduction testing at the start of the study and at 52 weeks.

What are the possible benefits and risks of participating?

The results from the study are of great importance to patients who will be treated in the future for CTS. They will show the long-term effects of treatment of CTS with a wrist splint. The use of a wrist splint does not have any complications and participation in the study does not cause delayed treatment time compared with routine treatment.

Where is the study run from?

Department of Orthopedics, Hässleholm-Kristianstad-Ystad (Sweden)

When is the study starting and how long is it expected to run for?

January 2018 to December 2022

Who is funding the study?
Investigator initiated and funded

Who is the main contact?
Dr Kamelia Tadjerbashi

Contact information

Type(s)
Scientific

Contact name
Dr Kamelia Tadjerbashi

Contact details
J A Hedlunds väg 5
Kristianstad
Sweden
29185

Additional identifiers

Protocol serial number
2018/16

Study information

Scientific Title
Treatment of carpal tunnel syndrome with wrist splinting: a randomized controlled trial

Study objectives
Wrist splinting is effective for treatment of carpal tunnel syndrome.

Ethics approval required
Old ethics approval format

Ethics approval(s)
1. Approved 30/01/2018, Regional Ethical Review Board (Lund, Sweden), ref: 2018/16
2. Amendment approved 16/02/2021, Ethical Review Authority (Sweden), ref: 2021-00656

Study design
Multi-centre prospective assessor-blinded randomized clinical trial

Primary study design
Interventional

Study type(s)
Treatment

Health condition(s) or problem(s) studied

Carpal tunnel syndrome

Interventions

Current intervention as of 28/04/2021:

A total of 112 eligible patients who accept participation and provide informed consent will be randomized according to a computer-generated list to treatment with either rigid or soft wrist splint to be used at night and if possible during daytime, initially for 6 weeks.

Group A: Splint with metal bar

A standard splint with wrist in neutral position worn at night and if possible during daytime. If after 6 weeks the patient reports large improvement, no further treatment is given. If the patient reports small or no improvement, further treatment with splint is given for another 4 weeks. If the patient reports only small or no improvement after 10-week splinting the patient will be offered surgery. Patients who refuse further treatment with wrist splinting will be offered surgery. Surgery will not be performed before 12 weeks after treatment start. If symptom recurrence occurs after improvement, the patients will be offered 4 weeks of wrist splinting. If the patient reports small or no improvement the patient will be offered surgery. Patients who refuse further treatment with wrist splinting will be offered surgery.

Group B: Soft splint

The splint is worn at night and if possible during daytime. If at the end of the 6 weeks the patient reports large improvement, no further treatment is given. If the patient reports small or no improvement the patient is offered surgery. Surgery will not be performed before 12 weeks after treatment start. If the patients reports symptom recurrence the patient will receive 4 weeks of similar splint. If the patient reports small or no improvement the patient is offered surgery.

The splints will be fitted with a temperature monitoring device to ascertain the total time during which the splint has actually been worn. The trial participants will complete a questionnaire that includes the 6-item CTS symptoms scale (CTS-6), the 11-item disabilities of the arm, shoulder and hand (QuickDASH) scale, the Euro-Qol 5-dimensions (EQ-5D) health status and quality of life measure and the palmar pain scale at trial start and at 6, 12, 24 and 52 weeks after treatment start. The participants will undergo physical examination and nerve conduction testing at trial start and at 52 weeks. The trials primary outcome is the change in the CTS-6 score from trial start, to 6 and 12 weeks and the rate of carpal tunnel release surgery at 52 weeks.

From patient 113 and onwards, the randomization process and interventions will be exactly the same as described above, however, the trial participants will complete the questionnaire only at baseline, and at 6 and 12 weeks after treatment start, since the follow-up time for these patients be 12 weeks (time frame for the trial's first primary outcome measure). Patient 113 and onwards will undergo physical examination and nerve conduction testing at trial start but not at 52 weeks. No other changes will be made in the trial protocol for these patients.

Previous intervention:

A total of 112 eligible patients who accept participation and provide informed consent will be randomized according to a computer-generated list to treatment with either rigid or soft wrist splint to be used at night and if possible during daytime, initially for 6 weeks.

Group A: Splint with metal bar

A standard splint with wrist in neutral position worn at night and if possible during daytime. If after 6 weeks the patient reports large improvement, no further treatment is given. If the patient reports small or no improvement, further treatment with splint is given for another 4 weeks. If the patient reports only small or no improvement after 10-week splinting the patient will be offered surgery. Patients who refuse further treatment with wrist splinting will be offered surgery. Surgery will not be performed before 12 weeks after treatment start. If symptom recurrence occurs after improvement, the patients will be offered 4 weeks of wrist splinting. If the patient reports small or no improvement the patient will be offered surgery. Patients who refuse further treatment with wrist splinting will be offered surgery.

Group B: Soft splint

The splint is worn at night and if possible during daytime. If at the end of the 6 weeks the patient reports large improvement, no further treatment is given. If the patient reports small or no improvement the patient is offered surgery. Surgery will not be performed before 12 weeks after treatment start. If the patients reports symptom recurrence the patient will receive 4 weeks of similar splint. If the patient reports small or no improvement the patient is offered surgery.

The splints will be fitted with a temperature monitoring device to ascertain the total time during which the splint has actually been worn. The trial participants will complete a questionnaire that includes the 6-item CTS symptoms scale (CTS-6), the 11-item disabilities of the arm, shoulder and hand (QuickDASH) scale, the Euro-Qol 5-dimensions (EQ-5D) health status and quality of life measure and the palmar pain scale at trial start and at 6, 12, 24 and 52 weeks after treatment start. The participants will undergo physical examination and nerve conduction testing at trial start and at 52 weeks. The trials primary outcome is the change in the CTS-6 score from trial start, to 6 and 12 weeks and the rate of carpal tunnel release surgery at 52 weeks.

Intervention Type

Device

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

-

Primary outcome(s)

Current primary outcome(s) as of 13/11/2025:

1. Change in the 6-item CTS symptom score from baseline to 12 weeks
2. Rate of carpal tunnel release surgery at 52 weeks

Previous primary outcome(s):

1. Change in CTS symptoms, measured with the 6-item CTS symptoms scale at baseline, 6 weeks and 12 weeks
2. Rate of surgery at 52 weeks, measured in percent (proportion of patients that had surgery within 52 weeks)

Key secondary outcome(s)

Current key secondary outcome(s) as of 13/11/2025:

1. Change in the 6-item CTS symptoms score from baseline to 6weeks and 52weeks
2. Change in QuickDASH score from baseline to 12weeks and 52weeks
3. Change in patient satisfaction score at 12weeks and 52weeks
4. Change in EQ-5D index from baseline to 12weeks and 52weeks
5. Cost-effectiveness at 52weeks
6. Palmar pain score at 52weeks
7. Time to surgery within 52weeks
8. Duration of sick leave during 52weeks
9. Change in grip strength from baseline to 52weeks
10. Adverse events at 52weeks

Previous key secondary outcome(s):

1. TS symptoms, measured with the 6-item CTS symptoms scale score at 52 weeks
2. Activity limitations, measured with the 11-item disabilities of the arm, shoulder and hand (QuickDASH) scale score at baseline, 12 weeks and 52 weeks
3. Health status and quality of life, measured with the EQ-5D index at baseline, 12 weeks and 52 weeks
4. Grip strength, measured with the Jamar dynamometer at baseline and 52 weeks
5. Patient satisfaction, measured with the visual analogue scale (VAS) at 12 weeks and 52 weeks
6. Palmar pain, measured with the 2-item palmar pain scale at 52 weeks
7. Time to surgery, measured in weeks, within 52 weeks
8. Duration of sick leave, measured in days/weeks/months during 52 weeks
9. Adverse events

Completion date

31/12/2022

Eligibility

Key inclusion criteria

Current inclusion criteria as of 04/06/2018:

1. Primary, idiopathic carpal tunnel syndrome (CTS)
2. Age 25-65 years, either sex
3. Symptoms of classic or probable CTS according to the criteria in Katz hand diagram
4. Nerve conduction studies showing median neuropathy at the wrist and no other abnormalities or, in the presence of normal nerve conduction study results, two orthopedic or hand surgeons independently diagnose the patient as having CTS
5. Symptom duration of at least 1 month

Previous inclusion criteria:

1. Primary, idiopathic carpal tunnel syndrome (CTS)
2. Age 25-65 years, either sex
3. Symptoms of classic or probable CTS according to the criteria in Katz hand diagram
4. Nerve conduction studies showing median neuropathy at the wrist and no other abnormalities or, in the presence of normal nerve conduction study results, two orthopedic or hand surgeons

independently diagnose the patient as having CTS

5. Symptom duration of at least 1 month

6. Symptom severity score at least 1.8 on the 6-item CTS symptoms scale (CTS-6)

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

25 years

Upper age limit

65 years

Sex

All

Total final enrolment

142

Key exclusion criteria

1. CTS classified as severe (thenar atrophy or 2-point discrimination exceeding 8 mm in at least 1 finger)
2. Treatment of the study hand with a wrist splint in the past year
3. Previous steroid injection for CTS in the study hand
4. Inflammatory joint disease
5. Vibration-induced neuropathy
6. Polyneuropathy
7. Current pregnancy
8. Trauma to the study hand in the past year
9. Previous CTS surgery in the study hand
10. Inability to complete questionnaires due to language difficulties or cognitive disorder
11. Severe medical illness
12. Known abuse of drugs and/or alcohol

Date of first enrolment

04/06/2018

Date of final enrolment

21/12/2021

Locations

Countries of recruitment

Sweden

Study participating centre
Department of Orthopedics, Hässleholm-Kristianstad-Ystad
Sweden
29185

Sponsor information

Organisation
Region Skåne

ROR
<https://ror.org/03sawy356>

Funder(s)

Funder type
Other

Funder Name
Investigator initiated and funded

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		01/04/2026	25/03/2026	Yes	No
Protocol article	protocol	27/08/2019	29/08/2019	Yes	No